Skip to main navigation Skip to search Skip to main content

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer

  • A. G. Duffy
  • , O. V. Makarova-Rusher
  • , S. V. Ulahannan
  • , O. E. Rahma
  • , S. Fioravanti
  • , M. Walker
  • , S. Abdullah
  • , M. Raffeld
  • , V. Anderson
  • , N. Abi-Jaoudeh
  • , E. Levy
  • , B. J. Wood
  • , S. Lee
  • , Y. Tomita
  • , J. B. Trepel
  • , S. M. Steinberg
  • , A. S. Revenko
  • , A. R. MacLeod
  • , C. J. Peer
  • , W. D. Figg
    • T. F. Greten*
*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Fingerprint

Dive into the research topics of 'Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science